Dermatology Times August 2026 Print Recap

Author(s)Marie Bosslett, Assistant Editor

Learn more about the in-depth topics covered in the August 2026 issue of Dermatology Times.

The August issue of Dermatology Times includes a collection of thought-provoking articles and topics as we examine the emerging role of oral peptides in psoriasis and beyond, discuss tips for transitioning from medical to aesthetic practice, look at the advancement of zumilokibart, and more.

Related to this article

October 13th, 2026

Social Media Mythbusters: “Botox in a Bottle”

Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.

October 5th, 2026

Dermatology Times Monthly FDA and Pipeline Review: September 2026

New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.

October 13th, 2026

First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis

SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.

October 13th, 2026

Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life

In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.

October 13th, 2026

AI-Era Skincare Report Finds Widespread Gaps in Verifiable Product Claims

An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.

October 12th, 2026

Clinicians Weigh Vitiligo Treatment Strategies Across Age Groups

Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.

October 12th, 2026

Q&A: 3-Year Nemolizumab Data Reinforce Long-Term Disease Control in Atopic Dermatitis

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.

October 12th, 2026

Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps

Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.